Notes on MicroRNAs and AI in Functional Genomics

MicroRNAs

  • Context in the transcriptome

    • The genome is transcribed into the transcriptome, containing coding RNAs and non-coding RNAs.

    • Coding RNAs (mRNAs) represent less than 5% of total RNAs; in some estimates, less than 3% depending on evaluation.

    • Non-coding RNAs dominate the transcriptome: more than 80% of RNAs are non-coding.

    • Non-coding RNAs include tRNAs, ribosomal RNAs, long non-coding RNAs (lncRNAs), and small non-coding RNAs (sncRNAs).

    • Small non-coding RNAs are defined as <200 nucleotides; among sncRNAs, microRNAs (miRNAs) are a key class.

    • Long non-coding RNAs are >200 nucleotides.

    • MicroRNAs and small interfering RNAs (siRNAs) belong to the category of small regulatory RNAs involved in RNA silencing, but they are distinct.

  • What microRNAs are

    • Small, single-stranded, non-coding RNA molecules ~20–25 nucleotides in length: 20 \, \leq \, L \, \leq \, 25\text{ nt}.

    • Found across plants, animals, and viruses; involved in RNA silencing and post-transcriptional regulation of gene expression.

    • Do not code for proteins; instead, regulate gene expression after transcription.

    • Distinct from siRNAs (which are often exogenously derived and often act by perfect complementarity).

  • MicroRNA function and mechanism (broad picture)

    • miRNAs base-pair with complementary sequences in target mRNAs and silence gene expression.

    • Mechanisms include:

    • mRNA cleavage (endonucleolytic cutting) by associated protein machinery.

    • Destabilization of the mRNA by shortening its poly(A) tail, reducing mRNA stability and turnover.

    • Reduction of translation efficiency, preventing ribosome binding.

    • In mammals/animals, miRNA action is primarily through post-transcriptional regulation and often via destabilization rather than rapid mRNA cleavage.

    • The mRNA target is usually bound via base-pairing with the miRNA, enabling the RNA-induced silencing complex (RISC) to enact silencing.

  • miRNA biogenesis (step-by-step)

    • Genes encoding miRNAs are located in the nucleus and transcribed by RNA polymerase II (Pol II) into primary miRNA (pri-miRNA) transcripts.

    • Pri-miRNA forms a characteristic hairpin loop structure.

    • Drosha and DGCR8 form the microprocessor complex to trim pri-miRNA into a precursor miRNA (pre-miRNA).

    • Pre-miRNA is exported from the nucleus to the cytoplasm by Exportin-5 (XPO5).

    • In the cytoplasm, Dicer cleaves the hairpin to form a short double-stranded miRNA duplex.

    • Argonaute proteins, particularly AGO2, interact with Dicer to form the RISC with one strand degraded and the other strand (the guide strand) remaining bound.

    • The guide strand within RISC binds to target mRNA via imperfect or partial base pairing, often using the seed region for recognition, leading to silencing.

  • RISC and target silencing details

    • RISC (RNA-induced silencing complex) uses AGO proteins and the miRNA guide strand to recognize mRNA targets.

    • If binding occurs, either cleavage of the target mRNA or translational repression/degradation occurs, leading to silencing of the gene.

    • Two representations of the pathway (diagrams and narrative) illustrate: pri-miRNA → Drosha/DGCR8 processing → export → Dicer processing → AGO loading → RISC targeting mRNA → silencing.

  • MicroRNA examples (illustrative, not exhaustive)

    • Examples include let-7 family (example name often cited in literature) and miR-1; miR-16 is also commonly discussed in literature.

    • miRNAs can be represented as hairpin structures with a single-stranded mature miRNA portion and an opposing strand that is degraded.

  • MicroRNA and disease relevance

    • Dysregulation of miRNAs is linked to a wide range of diseases: hematological malignancies, various cancers, nervous system disorders (e.g., Alzheimer’s, Parkinson’s), gastrointestinal diseases, inflammatory conditions, and infections.

    • Because miRNAs regulate many targets, they can influence multiple pathways and cellular processes.

  • Therapeutic potential and challenges

    • miRNAs themselves are being explored for therapy, but their broad targeting and delivery complexities present challenges.

    • siRNAs are often considered for therapeutic silencing with more direct mRNA targets; however, both RNAi modalities can in principle regulate gene expression via RISCs.

    • A key therapeutic concept is to target disease-relevant pathways by modulating miRNA or siRNA activity, though delivery to specific tissues remains a major hurdle.

  • miRNA vs siRNA: key distinctions

    • siRNA (small interfering RNA)

    • Double-stranded RNA (dsRNA) that enters cells exogenously or is produced endogenously in some organisms.

    • Typically ~20–24 base pairs long; often designed for perfect complementarity to a single target mRNA.

    • Guides RISC to cleave the target mRNA with high specificity, leading to degradation.

    • miRNA (microRNA)

    • Endogenously encoded miRNA genes transcribed by Pol II; processed into mature miRNA that guides RISC.

    • Usually imperfect complementarity; often a single miRNA can target hundreds of endogenous mRNAs through partial base-pairing (seed-based interactions).

    • Can lead to mRNA degradation or translational repression depending on context.

  • RNA interference (RNAi) in practice

    • RNAi is the umbrella term for gene-silencing mechanisms driven by small RNAs such as siRNA and miRNA.

    • Both miRNA and siRNA pathways converge on RNA-induced silencing complex (RISC) and can suppress gene expression.

    • For experimental gene knockdown, siRNAs are the preferred tool because they can be delivered to cells more readily and designed for precise mRNA targets.

    • miRNAs occur naturally; leveraging them therapeutically requires careful design and delivery considerations to avoid unintended broad effects.

  • Examples from videos and classroom narratives

    • A short video illustrated basic miRNA biogenesis, RISC assembly, and mRNA silencing mechanisms.

    • An open-access video on RNA interference described siRNA and miRNA pathways, Dicer processing, RISC loading, and the seed-based targeting of mRNA by miRNA.

    • The “experimental biology” note emphasizes that in lab settings, researchers typically use siRNA for targeted gene silencing rather than relying on miRNA to achieve a knockdown from outside cells, due to delivery constraints.

RNA interference (RNAi): siRNA vs miRNA in more detail

  • What RNAi is

    • A set of cellular mechanisms that use small RNA molecules to direct gene silencing by targeting specific mRNAs for degradation or translational repression.

    • Mediated by the RNA-induced silencing complex (RISC) with Argonaute (AGO) proteins.

  • siRNA specifics

    • Derived from longer double-stranded RNAs; can be produced inside cells or delivered exogenously.

    • Length: typically about 20–24 base pairs.

    • Mechanism: siRNA duplex is loaded into RISC; the guide strand pairs perfectly with its mRNA target; Argonaute catalyzes cleavage of the target mRNA, followed by degradation.

    • Experimental use: highly efficient and specific knockdown; often used as a tool to silence a single gene in cell culture or in vivo experiments.

  • miRNA specifics

    • Endogenously encoded; function within the natural gene regulatory network.

    • Majority of miRNAs are around 21 nt in length when mature (often cited as ~21 nt for many miRNA/siRNA species).

    • Target recognition: usually through partial complementarity; the seed region (part of the miRNA) engages the target mRNA, enabling broad targeting across hundreds of mRNAs.

    • Outcome: can lead to mRNA degradation or translational repression depending on the context and target.

  • RISC and targeting logic

    • Both siRNA and miRNA guide strands form a complex with AGO within RISC.

    • siRNA: often perfect complementarity leads to direct cleavage of the target mRNA.

    • miRNA: partial complementarity yields translational repression and/or mRNA destabilization.

  • Practical takeaways for research and therapy

    • siRNA is the standard experimental tool for targeted knockdown of specific genes due to its precise targeting and well-understood delivery in controlled settings.

    • miRNA-based therapeutics face challenges due to their broad activity and complexity of regulatory networks; therapeutic development focuses on understanding and manipulating specific miRNA–target interactions.

  • Therapeutic status and challenges (RNAi context)

    • siRNA-based therapies have advanced to clinical trials in certain contexts, with a focus on delivery to specific tissues and minimizing off-target effects.

    • miRNA-based therapies are conceptually appealing for diseases where a single miRNA regulates multiple disease-relevant pathways, but delivery, specificity, and safety remain key hurdles.

  • RNAi in examples discussed in the transcript

    • HIV infection: siRNA targets HIV RNA to degrade transcripts and inhibit viral replication in macrophages; long-lasting inhibition observed in certain cell types.

    • Melanoma: phase I trial of systemic siRNA showing reductions in target mRNA and protein in skin cancer; demonstrates potential for RNA-based therapies.

    • Delivery challenges: degradation by nucleases and tissue/organ-specific delivery remain major obstacles requiring repeated dosing and careful formulation.

  • OpenAI/AI context and charts (brief cross-link)

    • AI and machine learning are increasingly used to model RNAi data, predict off-target effects, and optimize designs for knockdown or regulation.

AI in functional genomics: definitions, tools, and applications

  • What is artificial intelligence (AI)?

    • A set of technologies enabling computers to perform tasks that typically require human-like perception, understanding, translation, speech, reasoning, learning, and decision-making.

    • Broadly defined as a field concerned with building machines that can think, learn, reason, and act, often at scales beyond human capability.

  • Types and components of AI

    • Narrow/weak AI: designed for specific tasks (e.g., voice recognition).

    • General/strong AI: capable of understanding and learning across a wide range of tasks similar to human intelligence (conceptual, not yet realized at broad scale).

    • Machine learning (ML) is a core subset of AI, consisting of algorithms that learn from data.

    • Deep learning is a subfield of ML that uses large neural networks with multiple layers to learn representations from data.

    • Three ML paradigms:

    • Supervised learning: models trained with labeled data to predict or classify outcomes.

    • Unsupervised learning: models detect patterns and cluster data without labeled outcomes.

    • Reinforcement learning: models improve through feedback from actions and outcomes, guided by rewards.

  • AI in biomedical data and functional genomics

    • AI/ML are already embedded behind the scenes in many bioinformatics tools and databases (e.g., BLAST, cBioPortal, TCGA analyses, proteomics pipelines).

    • AI enables handling multi-omics data (genomics, transcriptomics, proteomics, epigenomics) and integrating them to build predictive models and mechanistic hypotheses.

    • AI accelerates discovery, e.g., drug repurposing, predicting drug–target interactions, and modeling gene–phenotype relationships.

  • Practical uses of AI in functional genomics (examples from the transcript)

    • Automating workflows and reducing human error in data processing and analysis.

    • Pattern recognition to map signaling pathways and regulatory networks; rapid processing of large datasets makes high-throughput analyses feasible.

    • Multi-omics integration to understand disease circuits, tissue-specific gene regulation, and patient stratification.

    • Predictive modeling for drug discovery and repurposing (e.g., beta-blockers in cancer discovery through pattern recognition and data integration).

    • Personalised medicine: using genomic data to tailor treatments to individuals (genetic drivers, regulators, and tissue context).

    • Single-cell resolution analyses and spatial transcriptomics to map cellular circuits and how they change with disease progression or treatment.

  • OpenAI and genomic secondary analysis (conceptual overview)

    • Machine learning models process and predict genetic variations associated with diseases, drug resistance, and therapeutic responses.

    • Open-source tools and ML frameworks support processing genomic data and building predictive models; these resources facilitate rapid, scalable analyses.

    • Personalised medicine pipelines: models analyze patient genomics to propose tailored therapies.

    • Data resources and tools: data processing pipelines, databases, and ML frameworks enable researchers to assemble and analyze large datasets efficiently.

  • The role of big data in AI-enabled genomics

    • AI shines when there is a large volume of data (many patients, many measurements across genes, transcripts, proteins).

    • Big data enables pattern discovery, network inference, and causal reasoning that are difficult with small datasets.

  • A bold vision: causality and circuit-level understanding

    • Some visions of AI-driven medicine begin with genetic causality and profiling molecular phenotypes to understand tissue- and cell-type-specific effects of variants.

    • Single-cell and multi-omics data can reveal regulatory circuits, enabling targeted interventions (e.g., perturbing a regulator to alter disease states).

    • Approaches described include modal integration of genetic variants, regulatory maps, and single-cell data to identify driver genes and regulatory elements.

  • Data integration and causality tools

    • Mediation analysis and Mendelian randomization are used to understand how genetic variants act through intermediate molecular phenotypes.

    • The goal is to predict the causal pathways from genotype to phenotype, aiding targeted therapy development.

  • Translational vision: from data to intervention

    • By identifying upstream regulators or circuit elements, researchers aim to modulate gene expression to restore healthy states (e.g., restoring myelination in neurons, thermogenesis in adipocytes).

    • Genome editing (e.g., CRISPR-Cas9) and other programmable tools can alter regulators or target sites to achieve therapeutic effects.

  • The collaborative and governance aspect

    • AI in biomedicine benefits from cross-disciplinary collaboration among computer science, biology, chemistry, engineering, and health disciplines.

    • A coordinated ecosystem is needed to translate AI discoveries into clinical practice responsibly and equitably.

  • A caveat about limits and ethics

    • AI in biology comes with practical and ethical considerations:

    • Data privacy and consent for patient data.

    • Algorithmic bias and transparency; ensuring reproducibility.

    • Accountability for AI-driven decisions affecting patient care.

    • Governance and regulation to ensure safety and societal benefit.

    • The future holds great potential but requires careful governance, safety checks, and human oversight.

  • ChatGPT and genomic databases: can ChatGPT replace databases/tools?

    • ChatGPT (a large language model) can access training data and respond to questions, but it does not fetch or process raw genomic data from specialized databases in real time.

    • Limitations of ChatGPT for functional genomics:

    • It cannot perform precise data analyses or fetch exact numeric results (e.g., expression fold-changes, p-values) from public datasets in real time.

    • It provides limited or no direct access to annotations, BLAST results, or downloadable datasets; it may lack proper references or up-to-date data in free versions.

    • It is not a substitute for dedicated genomic databases (e.g., NCBI, TCGA, GTEx) for rigorous analyses or research-grade results.

    • Conclusion: as of the transcript, ChatGPT cannot replace genomic databases/tools for precise, verifiable analyses; it is a helpful assistant for concepts, planning, and high-level explanations but not a stand-alone data workbench.

  • Practical guidance and exam-oriented tips (from the transcript)

    • When answering MCQs, read carefully, justify why statements are true or false, and articulate the reasoning (e.g., experimental biology typically uses siRNA for gene knockdown due to delivery considerations; miRNA is endogenous and not generally used as a direct knockdown tool in experiments).

    • Distinguish between terms (miRNA vs siRNA) and understand their origins, processing steps, and functional outcomes.

    • For short-answer questions on AI in functional genomics, emphasize big data, automation, multi-omics integration, and the role of ML/DL in speeding analysis and discovery, with concrete examples.

    • Ethical considerations when discussing AI: highlight governance, data privacy, bias, and human oversight.

  • Quick glossary (key terms to remember)

    • miRNA: microRNA, ~20–25 nt, endogenous, post-transcriptional regulation via RISC; can repress translation or degrade target mRNAs.

    • siRNA: small interfering RNA, ~20–24 bp, exogenous or endogenous; guides RISC to cleave target mRNA with high specificity.

    • RISC: RNA-induced silencing complex, contains Argonaute (AGO) proteins; the guide strand directs silencing.

    • Drosha/DGCR8: Microprocessor complex that cleaves pri-miRNA to form pre-miRNA in the nucleus.

    • Dicer: Cytoplasmic enzyme that processes pre-miRNA into mature miRNA duplexes.

    • AGO2: A key Argonaute protein that interacts with miRNA/siRNA during silencing.

    • OpenAI/ChatGPT: Technologies described as open AI tools; powerful for language tasks but not a replacement for specialized genomic databases or analyses (as of current capabilities).

  • Takeaways for study and real-world relevance

    • MicroRNAs are central players in post-transcriptional gene regulation with implications across development, disease, and therapy.

    • siRNA and miRNA pathways illustrate how cells regulate gene expression and how researchers can harness these processes for experimental and therapeutic goals.

    • AI and ML are transforming functional genomics by enabling big-data analyses, multi-omics integration, and accelerated discovery; however, careful attention to data quality, validation, and ethics is essential.

    • While AI tools (including language models) can support bioscience work, they complement rather than replace established databases, experimental methods, and rigorous statistical analyses.

Exam-style prompts and practical notes

  • Example MCQ discussed in the transcript

    • Question: Which statements are correct?

    • Statement 1: MicroRNAs are exogenous double-stranded RNA uptaken by cells, whereas siRNA is endogenous single-stranded RNA.

    • Statement 2: MicroRNA mainly serves as drug targets/therapeutic agents and biomarker tools, while siRNA mainly serves as a therapeutic agent.

    • Answer discussed: Neither statement is correct as written (the exam dialogue concluded that the likely correct answer is that neither one nor two are correct) and emphasized that siRNA is the experimental tool and miRNA is endogenous.

  • Short-answer guidance

    • Explain why siRNA is used in experimental gene inhibition (delivery, stability, and specificity) and why miRNA is endogenous and not typically used as a direct exogenous knockdown tool.

    • Mention big data, pattern recognition, and multi-omics integration as reasons AI is used in functional genomics.

Connections to foundational principles and real-world relevance

  • The non-coding transcriptome is large and functionally important; miRNAs are a major component of post-transcriptional regulation and can influence multiple pathways and disease states.

  • RNA interference represents a fundamental gene-silencing mechanism; understanding the nuances of siRNA vs miRNA informs both basic biology and therapeutic design.

  • AI/ML in genomics exemplifies how computational methods enable the handling of high-dimensional data to infer regulatory networks, predict disease risk, identify drug targets, and support precision medicine.

  • Ethical and practical considerations are essential when deploying AI in healthcare, including data privacy, bias, and the need for human oversight and validation.

Quick numerical recap (LaTeX-formatted)

  • Coding RNAs as a fraction of total RNAs: ext{coding RNAs} < 5\% \text{(some estimates } < 3\%)

  • Non-coding RNAs as a fraction of total RNAs: ext{non-coding RNAs} > 80\%

  • miRNA length: 20 \, \leq \, L \, \leq \, 25\text{ nt}

  • siRNA length: 20 \leq \text{length} \leq 24\text{ bp}

  • Mature miRNA/siRNA length commonly cited: \approx 21\text{ nt}

  • sncRNA length cutoff: \text{length} < 200\text{ nt}

  • Poly(A) tail significance (mRNA purification note): poly(A) tails are used for mRNA purification via poly-T capture during chromatography (no explicit numeric equation given)

  • Distinct roles and mechanisms summarized: mRNA cleavage, mRNA destabilization, and translation repression (depend on miRNA/siRNA and context)

This set of notes covers the major ideas, processes, examples, and implications discussed in the transcript, organized to support exam preparation and conceptual understanding of microRNAs, RNA interference, and the role of artificial intelligence in functional genomics.